Drug intelligence / Profile preview

N-cadherin neutralizing antibody

Development stage
Preclinical
Lead developer
Kagoshima University
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intraperitoneal
01

Overview

N-cadherin neutralizing antibody refers to a class of monoclonal antibodies designed to bind to and inhibit the activity of N-cadherin (Cadherin-2), a calcium-dependent cell-cell adhesion molecule. N-cadherin is often upregulated in various cancers during the epithelial-to-mesenchymal transition (EMT), where it promotes tumor cell motility, invasion, and metastasis. In the context of pancreatic cancer research, these antibodies are used to block the CD133/ERK/Slug signaling axis, which regulates EMT and the invasive potential of cancer stem cells. By neutralizing N-cadherin, these agents aim to reduce the migratory capacity of malignant cells and potentially limit metastatic spread. While several clones exist for research purposes (e.g., GC-4), they are primarily used as laboratory tools to investigate the role of N-cadherin in tumor progression.

Other names
N-cadherin neutral antibodyanti-N-cadherin antibody
02

Targets

CDH2 (N-cadherin)

Beyond the preview

Go deeper on N-cadherin neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-cadherin neutralizing antibody.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call